tbuckley/cabot-search huggingface dataset:
P223 The patient’s role in the choice of new inhaler devices and dosing regimens for asthma and copd: a preference study
Authors: T Robinson
Journal: Thorax (2016)

<h3>Introduction</h3> Management guidelines for asthma and COPD guide which inhaled therapies should be prescribed, but not what type of device. There appears to be little evidence in the literature to support if patient involvement influences how concordant patients are with inhaled therapies. <h3>Aims and objectives</h3> The aim was for patients to rate inhaler devices and dosing regimens so that discreet choices could be made when adding new drugs and devices to the local joint primary and secondary care prescribing formulary. <h3>Methods</h3> 40 patients with asthma (n = 20) or COPD were purposively selected to participate in the study. 30 patients were seen on a one to one basis and ten patients with COPD seen in a patient education group. They were each given devices not normally prescribed in the locality (asthma = 5, COPD = 6). They were given 2 sets of instructions on how to load and use each device, a patient information leaflet (PIL) produced by the manufacturer, and one designed by the local nursing team. Each patient was asked to complete a 5-point questionnaire. Questions included: Which device did they prefer the most Which device did they least prefer Would they like once daily or twice daily maintenance medication Would they like all their drugs in one type of device or different devices Did they prefer the manufacturers PIL or the locally devised one <h3>Results</h3> Preloaded devices were much preferred by both patient groups, although only 2 of the 6 devices needed loading. Once daily dosing regimens were preferred over twice daily dosing (N = 28). Patients comprehensively preferred the local instructions for use compared to the PIL (N = 38). Patients preferred to have the same device for all their inhaled therapies (N = 32). <h3>Conclusions</h3> Most new drug delivery systems prescribed to patients are selected by clinicians. This small-scale study highlighted the importance of patient involvement when clinicians prescribe devices and dosing regimens. Manufacturers need to look at simplifying PILs, which may increase patients’ ability to use their device correctly.
S61 Risk factors and short-term outcomes of developing postoperative pulmonary complications after vats lobectomy
Authors: P Agostini, ST Lugg, K Adams, T Smith, M Kalkat, PB Rajesh, RS Steyn, B Naidu, A Rushton, E Bishay
Journal: Thorax (2016)

<h3>Introduction</h3> Postoperative pulmonary complications (PPC), such as pneumonia and atelectasis are associated with poor outcomes following thoracotomy and lung resection, with risk factors identified.<sup>1,2</sup> Video-assisted thoracoscopic surgery (VATS) is increasingly performed, however, there are varying reports regarding the incidence of PPC with little is known about their effect on short-term outcomes or potential risk factors. <h3>Methods</h3> A prospective observational study of consecutive patients undergoing VATS lobectomy was performed in a regional centre (2012–2016). Exclusion criteria included re-do VATS/completion lobectomy. All patients received physiotherapy assessment/intervention as necessary from postoperative day 1 (POD1). The presence of PPC was determined daily using the Melbourne Group Scale. Outcomes included hospital length of stay (LOS), intensive therapy unit (ITU) admission and hospital mortality. <h3>Results</h3> 287 patients underwent VATS lobectomy, 2 patients undergoing completion lobectomy were excluded. Of 285 patients; 137 were male (48%), median (IQR) age of 69 years (13) and mean (±SD) FEV1 of 87% (±19). PPC developed in 21 patients (7.4%); the median day that PPC developed was postoperative day 3 (Figure 1). Patients who developed a PPC had a significantly longer hospital LOS (4 vs 3 days), higher rate of ITU admission (25% vs 0%) and higher hospital mortality (14% vs 0%) (p &lt; 0.001). Current smoking and COPD diagnosis were significantly different on univariate analysis (p &lt; 0.05), but on forward stepwise logistic regression, only current smoking was a significant independent risk factor for PPC (p = 0.015). Those with PPC required significantly more physiotherapy contacts/time, with more specific pulmonary therapy and emergency out-of-hours therapy. <h3>Conclusions</h3> Patients undergoing VATS remain at risk of developing a PPC associated with significantly worse short-term morbidity and mortality. Patients that develop a PPC following VATS required increased postoperative physiotherapy compared to non-PPC patients. Current smoking is an independent risk factor for PPC development following VATS, thus vigorous addressing of preoperative smoking cessation is urgently needed. <h3>References</h3> Agostini P, <i>et al</i>. Postoperative pulmonary complications following thoracic surgery: are there any modifiable risk factors? <i>Thorax</i> 2010;<b>65</b>(9):815–8. Lugg ST, <i>et al</i>. Long-term impact of developing a postoperative pulmonary complication after lung surgery. <i>Thorax</i> 2016;<b>71</b>(2):171–6.
The early metabolic effect of zolendronic acid on FDG-PET scans in patients with bone metastasis.
Authors: B. Oyan, N. Alan Selcuk, C. Akosman, C. Ordu
Journal: Journal of Clinical Oncology (2011)

e21168 Background: 18-fluorodeoxyglucose (FDG) positron emission tomography combined with computerized tomography (FDG-PET/CT) is widely used in staging of several cancers. Any agent that can cause a decreased uptake of FDG by tumor cells can lead to inaccurate staging of the cancer. Bisphosphonates are routinely administered to patients with bone metastasis to reduce the morbidity related to skeletal events. Recently, it was shown that zolendronic acid (ZA) has also antitumor effects due to several potential mechanisms, including the induction of tumor cell apoptosis, inhibition of tumor cell invasion/migration, activation of anticancer tumor responses and anti-angiogenic effects. Although we know that the interval between the last dose of chemotherapy and the PET/CT study is important for reliable interpretation, the effect of ZA on maximum standardized uptake values (SUVmax) on FDG-PET scans in cancer pts with bone metastasis is not identified. Methods: The primary aim for this trial was to assess the change in maximum SUVs of tumor lesions on PET/CT, 72 hour after the administration of ZA therapy in pts with bone metastasis. Twelve pts (6 male, 6 female) with newly diagnosed cancer having bone metastasis on FDG-PET/CT were prospectively enrolled to this trial. Pts were chemotherapy-naïve. No prior or concurrent use of bisphosphonates was allowed. Pts received 4 mg of intravenous ZA and PET/CT was done 72 hours later. Results: The median age of pts was 59 years (38-70). The primary tumors were non-small cell lung cancer (n=7), breast cancer (n=3), renal cell carcinoma (n=1) and gastric neuroendocrine tumor (n=1). When baseline PET/CT was compared with the PET/CT that was done 72 hours after ZA administration, no significant change was detected in the SUVmax of the bone lesions and SUVmax of the primary lesion. In 3 pts, some bone lesions became metabolically unrecognizable after ZA administration, but the stage did not change in these pts. These lesions had a relatively low SUVmax on baseline PET/CT. Conclusions: Our results suggest that administration of ZA prior to staging with PET/CT does not seem to affect the FDG-uptake level of tumor lesions in PET/CT.
P3.02b-062 Safety of Necitumumab and Abemaciclib Combination Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Authors: Benjamin Besse, Johan Vansteenkiste, Patrick-Aldo Renault, Bente Frimodt-Moller, Grace Chao, Maciej Gil, Fabrice Barlesi
Journal: Journal of Thoracic Oncology (2017)
P3.02a-013 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial
Authors: D. Ross Camidge, Marcello Tiseo, Myung-Ju Ahn, Karen Reckamp, Karin Hansen, Sang-We Kim, Rudolf Huber, Howard West, Harry Groen, Maximilian Hochmair, Natasha Leighl, Scott Gettinger, Corey Langer, Luis Paz-Ares, Egbert Smit, Edward Kim, William Reichmann, Tim Clackson, David Kerstein, Frank Haluska, Dong-Wan Kim
Journal: Journal of Thoracic Oncology (2017)
Sympathetic Cardioneuropathy in Dysautonomias
Authors: David S. Goldstein, Courtney Holmes, Richard O. Cannon, Graeme Eisenhofer, Irwin J. Kopin
Journal: New England Journal of Medicine (1997)

The classification of dysautonomias has been confusing, and the pathophysiology obscure. We examined sympathetic innervation of the heart in patients with acquired, idiopathic dysautonomias using thoracic positron-emission tomography and assessments of the entry rate of the sympathetic neurotransmitter norepinephrine into the cardiac venous drainage (cardiac norepinephrine spillover). We related the laboratory findings to signs of sympathetic neurocirculatory failure (orthostatic hypotension and abnormal blood-pressure responses associated with the Valsalva maneuver), central neural degeneration, and responsiveness to treatment with levodopa-carbidopa (Sinemet).Cardiac scans were obtained after intravenous administration of 6-[18F]fluorodopamine in 26 patients with dysautonomia. Fourteen had sympathetic neurocirculatory failure--three with no signs of central neurodegeneration (pure autonomic failure), two with parkinsonism responsive to treatment with levodopa-carbidopa, and nine with central neurodegeneration unresponsive to treatment with levodopa-carbidopa (the Shy-Drager syndrome). The rates of cardiac norepinephrine spillover were estimated on the basis of concentrations of intravenously infused [3H]norepinephrine during catheterization of the right side of the heart.Patients with pure autonomic failure or parkinsonism and sympathetic neurocirculatory failure had no myocardial 6-[18F]fluorodopamine-derived radioactivity or cardiac norepinephrine spillover, indicating loss of myocardial sympathetic-nerve terminals, whereas patients with the Shy-Drager syndrome had increased levels of 6-[18F]fluorodopamine-derived radioactivity, indicating intact sympathetic terminals and absent nerve traffic. Patients with dysautonomia who did not have sympathetic neurocirculatory failure had normal levels of 6-[18F]fluorodopamine-derived radioactivity in myocardium and normal rates of cardiac norepinephrine spillover.The results of 6-[18F]fluorodopamine positron-emission tomography and neurochemical analyses support a new clinical pathophysiologic classification of dysautonomias, based on the occurrence of sympathetic neurocirculatory failure, signs of central neurodegeneration, and responsiveness to levodopa-carbidopa.
P53 Predicting poor outcomes in COPD patients deemed ‘low risk’ by dose score
Authors: LA Rigge, NA Coombs, M Johnson, D Culliford, L Josephs, N Williams, M Thomas, T Wilkinson
Journal: Thorax (2016)

<h3>Introduction</h3> COPD continues to cause a substantial symptom, mortality and financial burden in the UK. Current treatment strategies are predominantly reactive as insufficient evidence exists to successfully target clinical resource into pre-emptive ‘early interventions’. The DOSE (dyspnoea, obstruction, smoking status and exacerbation) score has been validated as a risk predictor for mortality, hospitalisation and poorer health status. However, only a small proportion of COPD patients with poor outcomes have high DOSE scores. We sought to establish if clinical characteristics can be used to pre-emptively identify those COPD patients vulnerable to future poor health status by using an electronic database of anonymised patient records-the Hampshire Health Record Analytical Database (HHRA). <h3>Methods</h3> Within our HHRA database COPD cohort, we identified a cohort of 6890 patients who fell into the ‘low risk’ category by DOSE score (&lt;4). Within this group, a subset met the criteria for poor COPD outcomes over the next four years, defined as; death (all cause), COPD related hospital admission, a DOSE score increase of ≥2 points or a subsequent DOSE score of ≥4 (high risk). We used logistic regression analysis to examine the association between demographic and clinical characteristics documented by Read code at baseline and those who subsequently fell into the poor outcomes subgroup. <h3>Results</h3> In our ‘low risk’ cohort of 6890 COPD patients, 5000 held sufficient data to be included in the analysis. After four years, 2211 (44.2%) of those 5000 patients fell into the poor outcomes subgroup. As shown in Table 1, poor future outcomes were significantly associated with age, high deprivation decile, low BMI, certain comorbidities, a raised eosinophil percentage (≥2%) and the prescription (in the preceding twelve months) of nebulised bronchodilators, inhaled bronchodilators and an ICS/LABA combination inhaler. A BMI of &gt;25 and rhinosinusitis were associated with a lower risk of poor future outcomes. <h3>Conclusions</h3> Poor future clinical outcomes appear to be associated with certain clinical characteristics in a COPD database cohort deemed low risk by DOSE score. These findings warrant further validation in a clinical cohort and investigation into the effect of pre-emptive optimisation of these characteristics on health outcomes.
P3.06-007 The Consequence of Incomplete Follow-up in Hospital-based Survival Study as Compared with National Vital Status-based Results
Authors: Youngjoo Lee, Jungnam Joo, Mihong Choi, Young-Joo Won, Jinhyuk Huh, Ji-Youn Han, Jin Soo Lee
Journal: Journal of Thoracic Oncology (2017)
P106 Improving five year survival in lung cancer: surveying patients and carers, HCPS and GPS
Authors: R Steyn, MD Peake
Journal: Thorax (2016)

<h3>Introduction</h3> The United Kingdom Lung Cancer Coalition (UKLCC) was established in 2005 with the primary goal of doubling five-year survival rates in lung cancer by 2015. Estimates suggest that the UKLCC has met this goal in England, with improvements also seen in Scotland, Wales and Northern Ireland. The UKLCC is now looking to set a new ambition to substantially raise five-year survival rates by 2025. <h3>Method</h3> The UKLCC surveyed 102 patients and carers, 148 healthcare professionals, and 1,003 general practitioners (GPs) asking questions related to improvement of five-year survival rates for lung cancer. <h3>Results</h3> <b>Awareness: </b>Over 40% of patients and carers stated they did not know that weight loss, tiredness and chest pain are possible symptoms of lung cancer. <b>Screening: </b>52% of HCPs believe their Government should introduce a national screening programme for lung cancer. <b>Early diagnosis: </b>68% of HCPs believe that prompt access to investigative testing including blood tests, chest x-rays and CT scans are the greatest challenge to rapid diagnosis. <b>Waiting times: </b>36% of patients were waiting over one month for confirmation of a suspected lung cancer diagnosis and 17% waited over two months. <b>Achievability of survival:</b> 49% of patients and carers believe surviving lung cancer for more than five years to be achievable. However, 65% of HCPs consider it difficult to achieve and 15% “completely unachievable”. <b>Local variation: </b>84% of the HCPs believe regional inequalities in health and care services have a moderate or major impact on lung cancer survival rates. <h3>Conclusion</h3> Analysis of the results shows that improvement in prevention, early-stage diagnosis and awareness of signs and symptoms among the public, could play a significant part in improving five-year survival. The results also show that patients and carers are more optimistic about the achievability of surviving lung cancer for more than five years (though this discounts patients who were not well enough to complete the survey) than HCPs.
Emergency endoscopic exploration of a pancreatic pseudocyst to retrieve a migrated pigtail stent
Authors: Gianfranco Donatelli, Jean-Loup Dumont, Fabrizio Cereatti, Thierry Tuszynski, Giovanni Calogero, Bertrand Vergeau, Bruno Meduri
Journal: Endoscopy (2017)

Endoscopic ultrasound (EUS)-guided drainage of pancreatic pseudocyst using double-pigtail plastic stents is a well-established technique with a high success rate (95 % – 100 %). Early adverse events, namely bleeding and perforation, occur in up to 5 % of the procedure [1] [2] [3].
US physician groups urge Congress to preserve key elements of Affordable Care Act
Authors: Michael McCarthy
Journal: BMJ (2017)

In letters to congressional leaders, five major US physician groups have called on legislators to make sure that any effort to repeal the Affordable Care Act is accompanied by replacement legislation that allows people who gained cover through the 2010 health reform law to keep their insurance and that preserves the consumer protections it established.

Since its passage in 2010, congressional Republicans have sought to repeal or defund the act, often called Obamacare, more than 50 times. Now that they have gained control of the House of Representatives, the Senate, and—with the election of Donald Trump—the presidency, Republican leaders have vowed to …
Role and Regulation of Heat Shock Proteins 90alpha and 90beta in Multiple Myeloma.
Authors: Manik Chatterjee, Sarika Jain, Thorsten Stühmer, Mindaugas Andrulis, Ute Ungethüm, Ralf-Jurgen Kuban, Kurt Bommert, Max Topp, Doris Krämer, Hans K. Müller-Hermelink, Herrmann Einsele, Greiner Axel, Ralf C. Bargou
Journal: Blood (2006)
Transplantation of Ex Vivo Expanded Allogeneic Mesenchymal Stem Cells with Bone Marrow Improved Osteogenesis and Bone Formation In Patients with Perinatal Hypophosphatasia
Authors: Takeshi Taketani, Rie Kanai, Aya Mihara, Chigusa Oyama, Seiji Fukuda, Seiji Yamaguchi, Koji Hattori, Yoshihiro Katsube, Hiroko Machida, Hiroe Ohnishi, Hajime Ohgushi
Journal: Blood (2010)
急性心不全の日本人患者に対するセレラキシンの多施設,ランダム化,二重盲検,偽薬対照第二相試験
Authors: Sato Naoki, Takahashi Wataru, Hirayama Atsushi, Ajioka Masayoshi, Takahashi Naoto, Okishige Kaoru, Wang Xingli, Maki Akio, Maruyama Hideki, Ebinger Ursula, Yamaguchi Masayuki, Pang Yinuo, Matsumoto Hiroki, Kawana Masatoshi
Journal: Circulation (2015)
Adaptor proteins NUMB and NUMBL promote cell cycle withdrawal by targeting ERBB2 for degradation
Authors: Maretoshi Hirai, Yoh Arita, C. Jane McGlade, Kuo-Fen Lee, Ju Chen, Sylvia M. Evans
Journal: Journal of Clinical Investigation (2017)

Failure of trabecular myocytes to undergo appropriate cell cycle withdrawal leads to ventricular noncompaction and heart failure. Signaling of growth factor receptor ERBB2 is critical for myocyte proliferation and trabeculation. However, the mechanisms underlying appropriate downregulation of trabecular ERBB2 signaling are little understood. Here, we have found that the endocytic adaptor proteins NUMB and NUMBL were required for downregulation of ERBB2 signaling in maturing trabeculae. Loss of NUMB and NUMBL resulted in a partial block of late endosome formation, resulting in sustained ERBB2 signaling and STAT5 activation. Unexpectedly, activated STAT5 overrode Hippo-mediated inhibition and drove YAP1 to the nucleus. Consequent aberrant cardiomyocyte proliferation resulted in ventricular noncompaction that was markedly rescued by heterozygous loss of function of either ERBB2 or YAP1. Further investigations revealed that NUMB and NUMBL interacted with small GTPase Rab7 to transition ERBB2 from early to late endosome for degradation. Our studies provide insight into mechanisms by which NUMB and NUMBL promote cardiomyocyte cell cycle withdrawal and highlight previously unsuspected connections between pathways that are important for cardiomyocyte cell cycle reentry, with relevance to ventricular noncompaction cardiomyopathy and regenerative medicine.
Effective Immune Response In Patients Who Have Hematologic Malignancies After Vaccination with Inactivated Influenza A (H1N1) 2009 Monovalent Vaccine
Authors: Yiqing Xu, Nanda K Methuku, Praveena Coimbatore, Theresa Fitzgerald, Yiwu Huang, Ying-Yi Xiao, Murali Pagala, William B. Solomon, Alan B Astrow, Philip Rubin, John Treanor, Howard Minkoff, Jay Cooper
Journal: Blood (2010)
P3.04-006 The Effect of Preoperative Multi-Disciplinary Support Commenced at Outpatient Clinic on Lung Cancer Patients
Authors: Masafumi Kataoka, Daisuke Okutani, Ema Mitsui, Miwa Baba, Tamami Okutani, Haruyuki Kawai, Kazuhiro Watanabe, Takefumi Niguma, Masashi Koizumi, Toshie Hiramatsu, Michiyo Kayahara, Sachiko Suda, Toshinori Ohara
Journal: Journal of Thoracic Oncology (2017)
P1.07-002 G1T28, a Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Topotecan for Previously Treated Small Cell Lung Cancer: Preliminary Results
Authors: Lowell Hart, Patrick Roberts, Renata Ferrarotto, Rodolfo Bordoni, Paul Conkling, Tejas Patil, Caio Max Rocha Lima, Taofeek Owonikoko, Steven Schuster, Robert Jotte, Robert Hoyer, Katie Stabler, Karen Makhuli, Raid Aljumaily, William Edenfield, Alexander Spira, Rajesh Malik, Geoffrey Shapiro
Journal: Journal of Thoracic Oncology (2017)
P3.02c-095 Italian Nivolumab Expanded Access Programme: Efficacy and Safety Data in Squamous Non-Small Cell Lung Cancer Patients
Authors: Lucio Crinò, Paolo Bidoli, Angelo Delmonte, Francesco Grossi, Filippo De Marinis, Andrea Ardizzoni, Fabiana Vitiello, Marina Garassino, Hector Soto Parra, Enrico Cortesi, Frederico Cappuzzo, Michele Maio, Marcello Tiseo, Daniele Turci, Silvia Quadrini, Marco Bregni, Alessandro Morabito, Antonio Palla, Diana Giannarelli, Domenico Galetta
Journal: Journal of Thoracic Oncology (2017)
Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richter’s Syndrome Transformation in Chronic Lymphocytic Leukemia.
Authors: Davide Rossi, Chiara Lobetti Bodoni, Elisa Genuardi, Luigia Monitillo, Daniela Drandi, Clara Deambrogi, Michaela Cerri, Irene Ricca, Alberto Rocci, Simone Ferrero, Elisa Bernocco, Daniela Capello, Lorenzo De Paoli, Luciana Bergui, Michela Boi, Paola Omedè, Massimo Massaia, Corrado Tarella, Roberto Passera, Mario Boccadoro, Gianluca Gaidano, Marco Ladetto
Journal: Blood (2008)
P2.03b-037 Prognostic Impact of 1st-Line Treatment and Molecular Testing in Advanced NSCLC in France - Results of the IFCT-PREDICT.amm Study
Authors: Jacques Cadranel, Elisabeth Quoix, Michael Duruisseaux, Sylvie Friard, Marie Wislez, Catherine Daniel, Elizabeth Fabre, Anne Madroszyk, Virginie Westeel, Patrick Merle, Hervé Léna, Eric Dansin, Julien Mazieres, Arnaud Scherpereel, Sandrine Hiret, Coureche Kaderbhai, Pierre-Jean Souquet, Pascale Missy, Alexandra Langlais, Franck Morin, Gérard Zalcman, Denis Moro-Sibilot, Fabrice Barlesi
Journal: Journal of Thoracic Oncology (2017)
Aberrant Expression of the Homeobox Gene CDX2 in Acute Myeloid Leukemia.
Authors: Claudia Scholl, Dimple Bansal, Konstanze Dohner, Karina Eiwen, Benjamin H. Lee, Frank G. Rucker, Richard F. Schlenk, Lars Bullinger, Hartmut Dohner, D. Gary Gilliland, Stefan Frohling
Journal: Blood (2006)